Praxis Secures FDA Priority Review for Relutrigine NDA in SCN2A/8A DEEs, PDUFA Set for Sept 27
PRAX has more than doubled off its 52-week low of $26.7.
Summary
Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for relutrigine, granting it Priority Review for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA has set a PDUFA target action date of September 27, 2026. This follows the successful NDA submission for relutrigine, as noted in the company's recent 10-K, and marks a significant step towards commercialization. The Priority Review designation underscores the FDA's recognition of relutrigine's potential to address a critical unmet medical need, as it would be the first disease-modifying therapy for these devastating and fatal conditions. This development significantly de-risks the drug's path to market and could unlock a substantial new revenue stream for Praxis, especially given its Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy Designations. Investors should closely monitor the PDUFA date for the final approval decision and the company's ongoing launch preparations.
At the time of this announcement, PRAX was trading at $279.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7B. The 52-week trading range was $26.70 to $356.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.